Autobahn Therapeutics, Inc.
Autobahn aims to improve life health for people affected by CNS disorders by driving the regenerative power of the human body.
Funding history
About Autobahn Therapeutics, Inc.
How much funding has Autobahn Therapeutics, Inc. raised?
Autobahn Therapeutics, Inc. has raised $100.8M in total funding. The most recent round was Series B.
Where is Autobahn Therapeutics, Inc. headquartered?
Autobahn Therapeutics, Inc. is headquartered in San Diego, CA.
What does Autobahn Therapeutics, Inc. do?
Autobahn aims to improve life health for people affected by CNS disorders by driving the regenerative power of the human body.
What problem does Autobahn Therapeutics, Inc. solve?
People affected by rare and prevalent CNS disorders face a progressive, debilitating disease course that current treatments don't adequately address.
What's Autobahn Therapeutics, Inc.'s solution?
Autobahn develops regenerative, orally administered small-molecule medicines, led clinically by elunetirom, that aim to restore the brain to a healthier state.
What makes Autobahn Therapeutics, Inc. different?
Its proprietary brain-targeting chemistry platform creates prodrugs with tunable ratios of central-vs-peripheral exposure, paired with biomarker-driven development to show on-target activity early in the clinic.
What makes Autobahn Therapeutics, Inc. notable?
Autobahn Therapeutics was co-founded out of Oregon Health & Science University (OHSU) research and has raised over $200M, including a $100M Series C led by Newpath Partners and a Series B co-led by ARCH Venture Partners.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 27, 2026.